BIOMARIN PHARMACEUTICAL INC Revenues
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Revenues of $373.45 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-04-27
- BIOMARIN PHARMACEUTICAL INC revenues for the quarter ending 2018-03-31 was $373.45M, a 22.95% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC revenues for the quarter ending 2017-12-31 was $358.31M, a 19.40% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC revenues for the quarter ending 2017-09-30 was $334.15M, a 19.38% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC revenues for the quarter ending 2017-06-30 was $317.45M, a 5.77% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC revenues for fiscal 2017 was $1.31B, a 17.62% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC revenues for fiscal 2016 was $1.12B, a 25.50% increase from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC revenues for fiscal 2015 was $889.89M, a 18.77% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC revenues for fiscal 2014 was $749.28M, a 36.61% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $373.45M 10-Q · filed 2018-04-27 | $731.75M derived: sum of 2 quarters · filed 2018-04-27 | $1.07B derived: sum of 3 quarters · filed 2018-04-27 | $1.38B derived: sum of 4 quarters · filed 2018-04-27 | ||||
| 2017-12-31 | $358.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $692.45M derived: sum of 2 quarters · filed 2018-02-26 | $1.01B derived: sum of 3 quarters · filed 2018-02-26 | $1.31B 10-K · filed 2018-02-26 | ||||
| 2017-09-30 | $334.15M 10-Q · filed 2017-10-31 | $651.60M derived: sum of 2 quarters · filed 2017-10-31 | $955.34M 10-Q · filed 2017-10-31 | $1.26B derived: sum of 4 quarters · filed 2018-04-27 | ||||
| 2017-06-30 | $317.45M 10-Q · filed 2017-08-02 | $621.19M 10-Q · filed 2017-08-02 | $921.28M derived: sum of 3 quarters · filed 2018-04-27 | $1.20B derived: sum of 4 quarters · filed 2018-04-27 | ||||
| 2017-03-31 | $303.75M 10-Q · filed 2018-04-27 | $603.84M derived: sum of 2 quarters · filed 2018-04-27 | $883.73M derived: sum of 3 quarters · filed 2018-04-27 | $1.18B derived: sum of 4 quarters · filed 2018-04-27 | ||||
| 2016-12-31 | $300.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $579.99M derived: sum of 2 quarters · filed 2018-02-26 | $880.12M derived: sum of 3 quarters · filed 2018-02-26 | $1.12B 10-K · filed 2018-02-26 | ||||
| 2016-09-30 | $279.90M 10-Q · filed 2017-10-31 | $580.03M derived: sum of 2 quarters · filed 2017-10-31 | $816.76M 10-Q · filed 2017-10-31 | $1.04B derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-06-30 | $300.13M 10-Q · filed 2017-08-02 | $536.87M 10-Q · filed 2017-08-02 | $764.80M derived: sum of 3 quarters · filed 2018-02-26 | $973.71M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-03-31 | $236.74M 10-Q · filed 2017-05-04 | $464.67M derived: sum of 2 quarters · filed 2018-02-26 | $673.58M derived: sum of 3 quarters · filed 2018-02-26 | $923.71M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2015-12-31 | $227.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $436.84M derived: sum of 2 quarters · filed 2018-02-26 | $686.98M derived: sum of 3 quarters · filed 2018-02-26 | $889.89M 10-K · filed 2018-02-26 | ||||
| 2015-09-30 | $208.90M 10-Q · filed 2016-11-03 | $459.04M derived: sum of 2 quarters · filed 2016-11-03 | $661.96M 10-Q · filed 2016-11-03 | $892.03M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $250.13M 10-Q · filed 2016-08-08 | $250.52M 10-Q · filed 2015-08-05 | $453.06M 10-Q · filed 2016-08-08 | $453.79M 10-Q · filed 2015-08-05 | $683.12M derived: sum of 3 quarters · filed 2017-02-27 | $859.67M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2015-03-31 | $202.92M 10-Q · filed 2016-05-02 | $203.26M 10-Q · filed 2015-05-05 | $432.99M derived: sum of 2 quarters · filed 2017-02-27 | $609.54M derived: sum of 3 quarters · filed 2017-02-27 | $801.32M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $230.07M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $406.62M derived: sum of 2 quarters · filed 2017-02-27 | $598.40M derived: sum of 3 quarters · filed 2017-02-27 | $749.28M 10-K · filed 2017-02-27 | $751.04M 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $176.55M 10-Q · filed 2015-11-02 | $176.85M 10-Q · filed 2014-10-28 | $368.34M derived: sum of 2 quarters · filed 2015-11-02 | $519.22M 10-Q · filed 2015-11-02 | $520.19M 10-Q · filed 2014-10-28 | $666.76M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $191.79M 10-Q · filed 2015-08-05 | $343.34M 10-Q · filed 2015-08-05 | $490.21M derived: sum of 3 quarters · filed 2016-02-29 | $627.09M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $151.55M 10-Q · filed 2015-05-05 | $298.43M derived: sum of 2 quarters · filed 2016-02-29 | $435.30M derived: sum of 3 quarters · filed 2016-02-29 | $572.11M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $146.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $283.75M derived: sum of 2 quarters · filed 2016-02-29 | $420.56M derived: sum of 3 quarters · filed 2016-02-29 | $548.49M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $136.87M 10-Q · filed 2014-10-28 | $273.68M derived: sum of 2 quarters · filed 2014-10-28 | $401.61M 10-Q · filed 2014-10-28 | $533.55M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | $136.81M 10-Q · filed 2014-07-31 | $264.74M 10-Q · filed 2014-07-31 | $396.68M derived: sum of 3 quarters · filed 2015-03-02 | $524.79M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | $127.93M 10-Q · filed 2014-05-02 | $259.87M derived: sum of 2 quarters · filed 2015-03-02 | $387.98M derived: sum of 3 quarters · filed 2015-03-02 | $512.00M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $131.94M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $260.06M derived: sum of 2 quarters · filed 2015-03-02 | $384.07M derived: sum of 3 quarters · filed 2015-03-02 | $500.72M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $128.12M 10-Q · filed 2013-10-28 | $252.14M derived: sum of 2 quarters · filed 2013-10-28 | $368.79M 10-Q · filed 2013-10-28 | $476.63M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-06-30 | $124.02M 10-Q · filed 2013-07-29 | $240.67M 10-Q · filed 2013-07-29 | $348.51M derived: sum of 3 quarters · filed 2014-02-26 | $461.94M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-03-31 | $116.65M 10-Q · filed 2013-04-29 | $224.50M derived: sum of 2 quarters · filed 2014-02-26 | $337.92M derived: sum of 3 quarters · filed 2014-02-26 | $448.55M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2011-12-31 | $107.85M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $221.27M derived: sum of 2 quarters · filed 2014-02-26 | $331.90M derived: sum of 3 quarters · filed 2014-02-26 | $441.36M 10-K · filed 2014-02-26 | ||||
| 2011-09-30 | $113.42M 10-Q · filed 2012-10-29 | $224.06M derived: sum of 2 quarters · filed 2012-10-29 | $333.51M 10-Q · filed 2012-10-29 | $435.13M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $110.63M 10-Q · filed 2012-08-02 | $220.09M 10-Q · filed 2012-08-02 | $321.70M derived: sum of 3 quarters · filed 2013-02-26 | $419.45M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $109.46M 10-Q · filed 2012-04-30 | $211.07M derived: sum of 2 quarters · filed 2013-02-26 | $308.82M derived: sum of 3 quarters · filed 2013-02-26 | $400.77M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $101.61M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $199.36M derived: sum of 2 quarters · filed 2013-02-26 | $291.31M derived: sum of 3 quarters · filed 2013-02-26 | $376.27M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $97.75M 10-Q · filed 2011-10-31 | $189.70M derived: sum of 2 quarters · filed 2011-10-31 | $274.65M 10-Q · filed 2011-10-31 | $361.74M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-06-30 | $91.95M 10-Q · filed 2011-08-01 | $176.90M 10-Q · filed 2011-08-01 | $263.99M derived: sum of 3 quarters · filed 2012-02-22 | $344.79M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-03-31 | $84.95M 10-Q · filed 2011-04-29 | $172.03M derived: sum of 2 quarters · filed 2012-02-22 | $252.84M derived: sum of 3 quarters · filed 2012-02-22 | $335.63M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2009-12-31 | $87.08M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $167.89M derived: sum of 2 quarters · filed 2012-02-22 | $250.68M derived: sum of 3 quarters · filed 2012-02-22 | $324.66M 10-K · filed 2012-02-22 | ||||
| 2009-09-30 | $80.81M 10-Q · filed 2010-10-29 | $163.59M derived: sum of 2 quarters · filed 2010-10-29 | $237.57M 10-Q · filed 2010-10-29 | |||||
| 2009-06-30 | $82.79M 10-Q · filed 2010-08-04 | $156.77M 10-Q · filed 2010-08-04 | ||||||
| 2008-12-31 | $296.49M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |